title: Buprenorphine therapy: an increasing challenge in oral and maxillofacial surgery.
abstract: Suboxone is a 4:1 mixture of buprenorphine and naloxone and Subutex is buprenorphine alone. The high affinity μ-receptor binding of buprenorphine (Suboxone and Subutex) renders other opioids ineffective. Inadequate procedural sedation, inadequate analgesia, and significant drug interactions complicate the treatment of patients taking Suboxone or Subutex. Careful planning and an understanding of buprenorphine pharmacology can minimize potential perioperative complications in patients taking Suboxone or Subutex.
authors.affiliation: Department of Oral and Maxillofacial Surgery, University of Washington, Seattle, WA 98195-7134, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Wasson
authors.forename: O Ross
authors.initials: OR
authors.lastname: Beirne
mesh_terms: D002047:Buprenorphine / Q000494:pharmacology / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage; D009292:Narcotic Antagonists / Q000494:pharmacology; D009294:Narcotics / Q000627:therapeutic use; D058850:Opiate Substitution Treatment; D019647:Oral Surgical Procedures; D010347:Patient Care Planning
chemical_list: D006993:Hypnotics and Sedatives; D009292:Narcotic Antagonists; D009294:Narcotics; D002047:Buprenorphine